IPX066

DRUG4 trials

Sponsors

Impax Laboratories, LLC

Conditions

Parkinson's Disease

Phase 2

A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa

CompletedNCT00869791

Impax Laboratories, LLCParkinson's Disease

Start: 2008-11-30End: 2009-06-30Updated: 2019-11-08

Phase 3

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).

CompletedNCT00974974

Impax Laboratories, LLCParkinson's Disease

Start: 2009-09-30End: 2011-03-31Updated: 2020-08-11

A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066

CompletedNCT01130493

Impax Laboratories, LLCParkinson's Disease

Start: 2010-05-31End: 2012-01-31Updated: 2019-10-29

Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study

CompletedNCT01411137

Impax Laboratories, LLCParkinson's Disease

Start: 2011-08-31End: 2013-03-31Updated: 2019-11-07

Related Papers

Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson’s Disease with Motor Fluctuations

Parkinson s Disease2018-10-224 citations

Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease.

2016-11-235 citations

Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.

2013-02-26131 citations